PolyPeptide Group AG announced the appointment of Juan-Jose Gonzalez as its new CEO, effective April 12, 2023. Juan-Jose Gonzalez (born 1972, Peruvian/US citizen) is a global business leader with a track record in the healthcare sector, most recently as CEO of Ambu A/S, a leading and fast-growing company in innovative single-use endoscopy listed on the Nasdaq OMX Copenhagen. Prior to this, he spent over 15 years with Johnson Johnson and Pfizer in positions of increasing responsibilities.

He has led complex businesses across the United States, Europe, and Asia Pacific. Mr. Gonzalez is a member of the Board of Directors of Straumann Group, a multinational oral health company, serving on both, the Audit Risk as well as the Human Resource Compensation Committees. He began his career at Procter Gamble as a regional sales manager in South America and later at McKinsey Co as a member of the Global Turnaround and Private Equity Practice in the United States.

Mr. Gonzalez holds a Bachelor in Industrial Engineering from the Universidad de Lima, a Master of Business Administration from the University of Notre Dame, and a Master of Technology Management from the University of Columbia. Mr. Gonzalez will join PolyPeptide on 12 April 2023 to take over the executive role from Peter Wilden who, after an adequate introduction period, will refocus on his role as Chairman of the Board of Directors of PolyPeptide Group AG.